Bottom line
Is RXD a good fund? The bottom line
RXD is an actively managed leveraged & inverse ETF from ProShares.
Its expense ratio is 0.95% — about $95 a year on every $10,000 invested, cheaper than 82% of leveraged & inverse funds we track.
It returned −21.6% over one year, −11.9% a year over five years, −19.9% a year over ten (as of Dec 31, 2025, per its prospectus).
With $5.3 million in net assets and 10 holdings, its largest position is Repurchase Agreement (37.3%) and the top 10 make up 89.9% of the portfolio.
What stands out
- Low cost: cheaper than 82% of leveraged & inverse peers
What to watch
- Concentrated: top 10 holdings are 89.9% of assets
- Small fund ($5.3 million) — small funds are likelier to close
Updated Nov 19, 2026
What RXD invests in
ProShares UltraShort Health Care (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the S&P Health Care Select Sector Index (the Index).
The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of health care companies included in the S&P 500 Index. The S&P 500 Index is designed to measure the performance of 500 of the largest companies listed and domiciled in the U.S. The Index includes health care companies in the following industries according to the Global Industry Classification Standard (GICS): health care equipment & supplies, health care providers & services; health care technology; biotechnology; pharmaceuticals; and life sciences tools & services. These companies are then weighted based on market capitalization. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March, June, and December. The Index is…
From the fund's prospectus (filed Sep 25, 2026).
RXD performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RXD | −21.6% | −11.9% | −19.9% |
| Leveraged & Inverse median | −7.7% | −11.8% | −13.5% |
Source: Fund prospectus, as of Dec 31, 2025
What RXD costs
On a $10,000 investment, RXD's 0.95% expense ratio costs about $95 a year. The prospectus estimates $4,430 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
RXD top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Repurchase Agreement | 37.33% |
| 2 | Repurchase Agreement | 23.49% |
| 3 | Repurchase Agreement | 17.62% |
| 4 | Repurchase Agreement | 12.92% |
| 5 | N/a | 1.14% |
| 6 | N/a | 0.33% |
| 7 | N/a | -0.34% |
| 8 | N/a | -0.41% |
| 9 | N/a | -0.54% |
| 10 | N/a | -1.63% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 89.9% of the fund. See all top 25 holdings and asset mix →